ライフサイエンスコーパス: trimethoprim

1 lindamycin, ciprofloxacin, penicillin-G, and trimethoprim).

2 -150.0 mumolL(-1) for both sulphadiazine and trimethoprim.

3 which code for resistance to sulfonamide and trimethoprim.

4 RSA was more susceptible to sulfamethoxazole/trimethoprim.

5 , including chloramphenicol, doxycycline and trimethoprim.

6 cular weight and is 82-fold more potent than trimethoprim.

7 darum became sensitive to polymyxin B and/or trimethoprim.

8 be selected by resistance to the antibiotic trimethoprim.

9 d that confers resistance to the antibiotic, trimethoprim.

10 oxoplasma gondii DHFR as the clinically used trimethoprim.

11 confer resistance to the antibacterial drug trimethoprim.

12 onfers resistance to the antibacterial agent trimethoprim.

13 most to the risk followed by lincomycin and trimethoprim.

14 eatment with the nontoxic FDA approved drug, trimethoprim.

15 in comparison with two standard inhibitors, trimethoprim (1) and piritrexim (2).

16 red daily co-trimoxazole prophylaxis (800 mg trimethoprim, 160 mg sulphamethoxazole) and followed up

17 79%; amoxicillin, 78%; cephalosporins, 31%; trimethoprim, 20%; piperacillin-tazobactam, 11%; chloram

18 diate (33.8-43.6%), tetracycline (30.4%) and trimethoprim (22.6%) intermediate to high heat stability

19 al degradation products of the antimicrobial trimethoprim (290 Da) is described.

20 (6.02; 95%CI: 3.31-8.73), sulfamethoxazole/ trimethoprim (4.49; 95%CI: 2.42-6.56), cefpodoxime (1.91

21 chloramphenicol, 49% (95% CI, 0.20 to 0.83); trimethoprim, 45% (95% CI, 0.22 to 0.74); piperacillin-t

22 .6%; gentamicin, 80.6%; and sulfamethoxazole/trimethoprim, 59.4%.

23 n, 100%; gentamicin, 88.0%; sulfamethoxazole/trimethoprim, 77.5%; levofloxacin, 58.5%; oxacillin, 54.

24 ngle-center study comparing sulfamethoxazole-trimethoprim 800/160 mg (SMZ/TMP) daily for 30 days foll

25 ibition and MIC values near or below that of trimethoprim against wild-type S. aureus.

26 Therefore, modification of trimethoprim, an antibacterial drug with no tumor growth

27 The weak bases trimethoprim and 4-phenylpyridine showed a similar patte

28 Analogue 17 was 50-fold more potent than trimethoprim and about twice as selective against T. gon

29 atter accumulation in these soils can retard trimethoprim and carbamazepine dissipation.

30 tance to chloramphenicol, sulphamethoxazole, trimethoprim and streptomycin.

31 Trimethoprim and sulfamethizole are both folate biosynth

32 e focus on combinations with the antibiotics trimethoprim and sulfamethizole, which had been standard

33 LEW1.WR1 rats with KRV and a combination of trimethoprim and sulfamethoxazole (Sulfatrim) beginning

34 Biotransformation rates increased for trimethoprim and sulfamethoxazole in the dark, when micr

35 sting that long-term treatment with combined trimethoprim and sulfamethoxazole prevented recurrent di

36 ed in the pilot-scale system (t1/2 < 0.5 d), trimethoprim and sulfamethoxazole were transformed more

37 ides, tetracyclines, macrolides, quinolones, trimethoprim and sulfamethoxazole, and rifampin.

38 sfully treated for PcP with a combination of trimethoprim and sulfamethoxazole.

39 broadly used combinatory antibiotic therapy, trimethoprim and sulfonamides.

40 anced sequestration of cationic or uncharged trimethoprim and uncharged carbamazepine, but did not af

41 d several that synergize with the antibiotic trimethoprim and/or sulfamethizole.

42 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylact

43 Filgrastim, sulfamethoxazole/trimethoprim, and acyclovir were administered prophylact

44 polymyxin B, amphotericin B, nalidixic acid, trimethoprim, and azlocillin (PANTA) was added, the tube

45 resistance to aminoglycosides, sulfonamides, trimethoprim, and beta-lactams.

46 that confers resistance to chloramphenicol, trimethoprim, and ciprofloxacin has been identified in B

47 chloramphenicols, tetracycline, macrolides, trimethoprim, and sulfonamides) was evaluated in surface

48 on was treated with amikacin and polymyxin B-trimethoprim, and the ulcer resolved over 3 weeks.

49 her alone or in combination with ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

50 rved by LDPI-MS in response to rifampicin or trimethoprim antibiotic treatment.

51 osis was made, and Bactrim (sulfamethoxazole-trimethoprim; AR Scientific, Philadelphia, Pa) and a reg

52 The continuously increasing use of trimethoprim as a common antibiotic for medical use and

53 sensitive to the clinically used antifolate, trimethoprim, because of a lack of potency against the d

54 ultaneous determination of sulphadiazine and trimethoprim by spectrophotometry in some bovine milk an

55 Here, we examine the effect the covalent trimethoprim chemical tag (A-TMP-tag) has on the SM imag

56 arately with NADPH, dihydrofolate and NADPH, trimethoprim), compounds 2 and 3 were optimized for inhi

57 l cells in the guts increased with increased trimethoprim concentration, ingestion and incorporation

58 e genetic elements, such as sulfamethoxazole-trimethoprim constins and class I integrons, and common

59 Here we demonstrate that trimethoprim derivatives can be used to selectively tag

60 lements on the plasmid encoded resistance to trimethoprim (dfrA), beta-lactams (blaZ), aminoglycoside

61 encoded tetracycline [tetA(A) and tetA(G)], trimethoprim [dfrA1, dfrA5, dfrA7, dfrA12, and dfrA15],

62 Trimethoprim dissipation was even slower in soils irriga

63 strategies for albendazole, chloramphenicol, trimethoprim, enrofloxacin, oxitetracycline and nicarbaz

64 Specifically, we designed an acrylamide-trimethoprim-fluorophore (A-TMP-fluorophore v2.0) electr

65 In daphnids exposed to 0.25 mg L(-1) trimethoprim for 24 h, the microbiota was strongly affec

66 ed in the animals exposed to 0.25-2 mg L(-1) trimethoprim for 48 h and then fed 14C-labeled algae.

67 c activities of their protein targets (i.e., trimethoprim for dihydrofolate reductase), thus disrupti

68 in, tetracycline, ciprofloxacin, vancomycin, trimethoprim, gentamicin, fusidic acid, rifampin, and mu

69 than the currently employed front-line drug trimethoprim (IC(50) = 46 microM).

70 ion used for extraction of sulphadiazine and trimethoprim in bovine milk.

71 crolides, 7 quinolones, 6 tetracyclines, and trimethoprim in chlorine-disinfected drinking water usin

72 nt of chronic diarrhea with sulfamethoxazole-trimethoprim in HIV-1-infected persons require revision,

73 sulfonamides, which is generally mixed with trimethoprim in pharmaceutical products, has been chosen

74 of the involvement of DNA repair enzymes in trimethoprim-induced cytotoxicity clearly indicates that

75 tase inhibitors characterized by an extended trimethoprim-like scaffold.

76 s wide distribution of ARGs for sulfonamide, trimethoprim, macroline, beta-lactams and chloramphenico

77 Trimethoprim, mecoprop, nonprescription pharmaceuticals,

78 Trimethoprim mediated concentration-dependent diminution

79 We examined effects of the antibiotic trimethoprim on microbiota of Daphnia magna and concomit

80 [(18)F]fluoropropyl-trimethoprim, or [(18)F]FPTMP, shows a greater than 100-

81 ond mutant that was resistant to lincomycin, trimethoprim, or rifampin.

82 Escherichia coli to grow in the presence of trimethoprim plus added sorbitol parallels the catalytic

83 were enrolled in the study; 29 patients used trimethoprim/polymyxin B drops, and 11 patients used flu

84 Removal of acetaminophen, ciprofloxacin, trimethoprim, propranolol, and carbamazepine (>80%) was

85 Transformation of trimethoprim, propranolol, and carbamazepine was attribu

86 terize a multi-peaked adaptive landscape for trimethoprim resistance by constructing all combinatoria

87 In contrast, trimethoprim resistance evolved in a stepwise manner, th

88 ined spectinomycin resistance gene aadA5 and trimethoprim resistance gene dfrA17.

89 eliminate the ability of the gene to confer trimethoprim resistance or have no effect on catalysis.

90 There was no significant difference in trimethoprim resistance rates between study and control

91 inations inhibit the growth and virulence of trimethoprim-resistant clinical Escherichia coli and Kle

92 propargyl-linked antifolates (PLAs) against trimethoprim-resistant dihydrofolate reductase (DHFR) fr

93 R inhibitors that are active against several trimethoprim-resistant enzymes.

94 S. aureus of 0.0125 mug/mL and a MIC versus trimethoprim-resistant S. aureus of 0.25 mug/mL.

95 cedure was applied to 22 feed samples, where trimethoprim, robenidine, or alpha- and beta-nandrolone

96 One of these antibiotics, trimethoprim, served as a global activator of secondary

97 Trimethoprim-SMX with rifampin is an efficient treatment

98 testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfadiazine with S. equi This study indica

99 famethoxazole as an acceptable surrogate for trimethoprim-sulfadiazine with S. equi.

100 ntimicrobial susceptibility test results for trimethoprim-sulfadiazine with Streptococcus equi subspe

101 e was detected for meropenem (2 strains) and trimethoprim-sulfamethonazole (1 strain).

102 dard oral regimen based on trial evidence is trimethoprim-sulfamethoxaxole (TMP-SMX) plus doxycycline

103 Intermediate resistance was detected for trimethoprim-sulfamethoxazole (10 strains) and clindamyc

104 Trimethoprim-sulfamethoxazole (160/800 mg twice daily fo

105 and, to a lesser extent, to kanamycin (19%), trimethoprim-sulfamethoxazole (17%), and gentamicin (11%

106 y selected isolates that were susceptible to trimethoprim-sulfamethoxazole (4 percent, P<0.001).

107 ), ethambutol (92%), and sulfamethoxazole or trimethoprim-sulfamethoxazole (70%).

108 ythromycin (73.9%), clindamycin (65.5%), and trimethoprim-sulfamethoxazole (80%); however, categorica

109 were successfully treated in all cases using trimethoprim-sulfamethoxazole (800 mg/160 mg) twice dail

110 . emergency departments to determine whether trimethoprim-sulfamethoxazole (at doses of 320 mg and 16

111 to at least ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug resistant [MDR]

112 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole (multidrug-resistant S. Ty

113 P = 0.016) and less frequently resistant to trimethoprim-sulfamethoxazole (OR = 0.38; 95% CI = 0.18

114 ce to amoxicillin-clavulanic acid (P = .03), trimethoprim-sulfamethoxazole (P = .01), and ciprofloxac

115 Ten days of trimethoprim-sulfamethoxazole (SXT) therapy reduces urin

116 Overall ciprofloxacin (CIP), trimethoprim-sulfamethoxazole (SXT), and cefazolin (CFZ)

117 us urinae has been described as resistant to trimethoprim-sulfamethoxazole (SXT), but the test medium

118 drug (27%), followed by phosphomycin (23%), trimethoprim-sulfamethoxazole (TMP-SMX) (9%), and cefuro

119 Trimethoprim-sulfamethoxazole (TMP-SMX) and fluoroquinol

120 Daily trimethoprim-sulfamethoxazole (TMP-SMX) and insecticide-

121 Long-term antibiotic therapy included oral trimethoprim-sulfamethoxazole (TMP-SMX) and rifampin, TM

122 Clindamycin and trimethoprim-sulfamethoxazole (TMP-SMX) are commonly pre

123 a 1:1 ratio to receive either clindamycin or trimethoprim-sulfamethoxazole (TMP-SMX) for 10 days.

124 drugs like HIV protease inhibitors (PIs) and trimethoprim-sulfamethoxazole (TMP-SMX) have known activ

125 Trimethoprim-sulfamethoxazole (TMP-SMX) is widely used i

126 up to 42 days, primarily in those receiving trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

127 44) or HIV exposed (n = 175) and prescribed trimethoprim-sulfamethoxazole (TMP-SMX) prophylaxis.

128 lin, 649 (58%) to streptomycin, 402 (36%) to trimethoprim-sulfamethoxazole (TMP-SMX), 355 (32%) to su

129 in, 19 isolates (43%) were nonsusceptible to trimethoprim-sulfamethoxazole (TMP-SMX), and all isolate

130 amikacin, ciprofloxacin, imipenem, rifampin, trimethoprim-sulfamethoxazole (TMP-SMX), and vancomycin.

131 re randomly assigned to receive clindamycin, trimethoprim-sulfamethoxazole (TMP-SMX), or placebo for

132 ortant has been the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current dru

133 Additionally, trimethoprim-sulfamethoxazole (TMP-SMX), used for opport

134 of urinary tract infections (UTI) caused by trimethoprim-sulfamethoxazole (TMP-SMX)-resistant Escher

135 Trimethoprim-sulfamethoxazole (TMP-SMZ) is an alternativ

136 Trimethoprim-sulfamethoxazole (TMP-SMZ) is the most effe

137 han other adults, and many receive long-term trimethoprim-sulfamethoxazole (TMP-SMZ) prophylactic the

138 these organisms is typically susceptible to trimethoprim-sulfamethoxazole (TMP-SMZ), and this theref

139 The efficacy of trimethoprim-sulfamethoxazole (TMP/SMX) in the preventio

140 onthly sulfadoxine-pyrimethamine (SP), daily trimethoprim-sulfamethoxazole (TS), or monthly dihydroar

141 d accounted for >/=40% (beta-lactams), >50% (trimethoprim-sulfamethoxazole , multidrug), or >70% (cip

142 ence implementing a protocolized approach to trimethoprim-sulfamethoxazole adverse drug reaction asse

143 Forty-two patients (35%) had 48 trimethoprim-sulfamethoxazole adverse drug reactions doc

144 zole, as compared with standard prophylaxis (trimethoprim-sulfamethoxazole alone).

145 showed that all strains were susceptible to trimethoprim-sulfamethoxazole and ciprofloxacin.

146 With trimethoprim-sulfamethoxazole and fluoroquinolones, the

147 icillin, imipenem, gentamicin, amikacin, and trimethoprim-sulfamethoxazole and had reduced susceptibi

148 was 0 of 46 (0%) and 6 of 47 (12.80%) in the trimethoprim-sulfamethoxazole and placebo groups, respec

149 ted in vivo by treatment with the antibiotic trimethoprim-sulfamethoxazole and possibly by coinfectio

150 boratory interpretation of in vitro MICs for trimethoprim-sulfamethoxazole and sulfamethoxazole and t

151 Additional prophylaxis included trimethoprim-sulfamethoxazole and valganciclovir.

152 th resistance to ampicillin, gentamicin, and trimethoprim-sulfamethoxazole and with susceptibility to

153 solates were found to have resistant MICs of trimethoprim-sulfamethoxazole and/or sulfamethoxazole.

154 tudy support a single breakpoint for testing trimethoprim-sulfamethoxazole and/or trimethoprim-sulfad

155 nded-spectrum penicillins, tetracycline, and trimethoprim-sulfamethoxazole are good treatment options

156 lfadiazine with S. equi This study indicates trimethoprim-sulfamethoxazole as an acceptable surrogate

157 venous vancomycin followed by 1 week of oral trimethoprim-sulfamethoxazole combination therapy.

158 cated cellulitis, the use of cephalexin plus trimethoprim-sulfamethoxazole compared to cephalexin alo

159 Current antiretroviral therapy or use of trimethoprim-sulfamethoxazole did not impact the risk of

160 n of E. coli isolates that were resistant to trimethoprim-sulfamethoxazole from women with community-

161 24-month visit for 428 children (214 in the trimethoprim-sulfamethoxazole group and 214 in the place

162 loped in 2 of 524 participants (0.4%) in the trimethoprim-sulfamethoxazole group and in 2 of 533 part

163 Weight gain in the trimethoprim-sulfamethoxazole group and the placebo grou

164 ed in 507 of 630 participants (80.5%) in the trimethoprim-sulfamethoxazole group versus 454 of 617 pa

165 ed in 487 of 524 participants (92.9%) in the trimethoprim-sulfamethoxazole group versus 457 of 533 pa

166 ) of 218 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 165 (85.5%) of 19

167 ) of 248 participants in the cephalexin plus trimethoprim-sulfamethoxazole group vs 171 (69.0%) of 24

168 had developed in 1 participant (0.2%) in the trimethoprim-sulfamethoxazole group.

169 to sulfisoxazole in 21.7% of strains and to trimethoprim-sulfamethoxazole in 21.0% resulted from pol

170 s of isoniazid-pyridoxine (coformulated with trimethoprim-sulfamethoxazole in a single fixed-dose com

171 Resistance to trimethoprim-sulfamethoxazole in Iran is low and this dr

172 While trimethoprim-sulfamethoxazole is considered first-line t

173 Trimethoprim-sulfamethoxazole is the preferred drug regi

174 ce interval (CI), 0.60-0.97; P =.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also

175 Trimethoprim-sulfamethoxazole or placebo taken orally, o

176 Additionally, each was randomized to trimethoprim-sulfamethoxazole or placebo.

177 l prophylaxis, which consisted of continuous trimethoprim-sulfamethoxazole plus at least 12 weeks of

178 Trimethoprim-sulfamethoxazole promotes the excision of a

179 nomic outcomes associated with no treatment, trimethoprim-sulfamethoxazole prophylaxis alone, antiret

180 ting and clinical criteria, as compared with trimethoprim-sulfamethoxazole prophylaxis alone.

181 A strategy of trimethoprim-sulfamethoxazole prophylaxis and antiretrov

182 Women received daily trimethoprim-sulfamethoxazole prophylaxis and insecticid

183 uster, which was controlled after systematic trimethoprim-sulfamethoxazole prophylaxis in exposed pat

184 ract infection, we evaluated the efficacy of trimethoprim-sulfamethoxazole prophylaxis in preventing

185 , and no further cases were identified after trimethoprim-sulfamethoxazole prophylaxis was introduced

186 lysis of data from a large clinical trial of trimethoprim-sulfamethoxazole prophylaxis, there was no

187 re as cost-effective as those that also used trimethoprim-sulfamethoxazole prophylaxis.

188 Significantly more patients underwent trimethoprim-sulfamethoxazole rechallenge after protocol

189 The introduction of a standard approach to trimethoprim-sulfamethoxazole rechallenge in the context

190 ting P carinii pneumonia; the combination of trimethoprim-sulfamethoxazole remains the first-line age

191 (clonal group A), in 28 of 55 isolates with trimethoprim-sulfamethoxazole resistance (51 percent) an

192 foreign travel significantly predicted both trimethoprim-sulfamethoxazole resistance (prevalence rat

193 cently recognized significant contributor to trimethoprim-sulfamethoxazole resistance in the United S

194 Cefprozil, cefaclor, and trimethoprim-sulfamethoxazole results differed the most,

195 Trimethoprim-sulfamethoxazole retains clinical efficacy,

196 cellulitis without abscess, the addition of trimethoprim-sulfamethoxazole to cephalexin did not impr

197 In settings in which MRSA was prevalent, trimethoprim-sulfamethoxazole treatment resulted in a hi

198 roportion of isolates that were resistant to trimethoprim-sulfamethoxazole was 63% in the prophylaxis

199 Trimethoprim-sulfamethoxazole was associated with slight

200 Trimethoprim-sulfamethoxazole was superior to placebo wi

201 em, levofloxacin, meropenem, tobramycin, and trimethoprim-sulfamethoxazole were comparable for the tw

202 n, penicillin, tetracycline, tilmicosin, and trimethoprim-sulfamethoxazole were determined for each i

203 Children not receiving trimethoprim-sulfamethoxazole with capillary whole blood

204 To determine whether cephalexin plus trimethoprim-sulfamethoxazole yields a higher clinical c

205 Co-trimoxazole (fixed-dose trimethoprim-sulfamethoxazole) prophylaxis administered

206 tracycline, ormetoprim-sulfadimethoxine, and trimethoprim-sulfamethoxazole).

207 Cephalexin, 500 mg 4 times daily, plus trimethoprim-sulfamethoxazole, 320 mg/1600 mg twice dail

208 onsusceptible to penicillin, macrolides, and trimethoprim-sulfamethoxazole, 8 had other resistance pa

209 n, 82%; clindamycin, 73%; levofloxacin, 73%; trimethoprim-sulfamethoxazole, 9%; and daptomycin, 9%.

210 occus spp. had high MICs of >4/76 mug/ml for trimethoprim-sulfamethoxazole, an antibiotic commonly us

211 luoroquinolones, 100 percent to rifampin and trimethoprim-sulfamethoxazole, and 92 percent to tetracy

212 pregnant women who received bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

213 ant women with HIV receiving bed nets, daily trimethoprim-sulfamethoxazole, and combination antiretro

214 to carbapenems but susceptible to aztreonam, trimethoprim-sulfamethoxazole, and fluoroquinolones.

215 -MRSA is usually susceptible to clindamycin, trimethoprim-sulfamethoxazole, and rifampin, but inducib

216 es were susceptible in vitro to clindamycin, trimethoprim-sulfamethoxazole, and rifampin.

217 ropenem, penicillin, rifampin, tetracycline, trimethoprim-sulfamethoxazole, and vancomycin.

218 penem, penicillin (PEN), tetracycline (TET), trimethoprim-sulfamethoxazole, and vancomycin.

219 Trimethoprim-sulfamethoxazole, ciprofloxacin, and pipera

220 d for the following agents: chloramphenicol, trimethoprim-sulfamethoxazole, ciprofloxacin, and rifamp

221 mportant difference favoring cephalexin plus trimethoprim-sulfamethoxazole, further research may be n

222 l agents, including ampicillin, ceftazidime, trimethoprim-sulfamethoxazole, gentamicin, and ciproflox

223 lumefantrine exposure, and in the absence of trimethoprim-sulfamethoxazole, lumefantrine exposure is

224 Immediate antimicrobial therapy with trimethoprim-sulfamethoxazole, nitrofurantoin, or fosfom

225 cases were treated with other beta-lactams, trimethoprim-sulfamethoxazole, or vancomycin.

226 ted CAS, the most common antimicrobials were trimethoprim-sulfamethoxazole, penicillin, and amoxicill

227 of travel-associated infections resistant to trimethoprim-sulfamethoxazole, sulfisoxazole, streptomyc

228 However, for children receiving trimethoprim-sulfamethoxazole, the risk of recurrent par

229 were sensitive to minocycline, doxycycline, trimethoprim-sulfamethoxazole, vancomycin, teicoplanin,

230 and N. otitidiscaviarum were susceptible to trimethoprim-sulfamethoxazole, while 8% of N. farcinica

231 Prophylaxis most frequently involves trimethoprim-sulfamethoxazole, with second-line therapie

232 cible clindamycin resistance (ICR) (n = 30), trimethoprim-sulfamethoxazole-resistant MRSA (n = 10), v

233 ciprofloxacin, clindamycin, gentamicin, and trimethoprim-sulfamethoxazole.

234 oxacin, clindamycin, gentamicin sulfate, and trimethoprim-sulfamethoxazole.

235 at Y. pestis, except for chloramphenicol and trimethoprim-sulfamethoxazole.

236 ompared by testing 567 staphylococci against trimethoprim-sulfamethoxazole.

237 e mice also received antibiotic therapy with trimethoprim-sulfamethoxazole.

238 0-day outpatient course of ciprofloxacin and trimethoprim-sulfamethoxazole.

239 lls/microL, despite anti-Pc prophylaxis with trimethoprim-sulfamethoxazole.

240 penicillin, erythromycin, tetracycline, and trimethoprim-sulfamethoxazole.

241 All infants also received high-dose trimethoprim-sulfamethoxazole.

242 osporins, fluoroquinolones, penicillins, and trimethoprim-sulfamethoxazole.

243 acin, gentamicin, rifampin, minocycline, and trimethoprim-sulfamethoxazole.

244 ftriaxone, ciprofloxacin, gentamicin, and/or trimethoprim-sulfamethoxazole.

245 penicillin, and 57 (82.6%) were resistant to trimethoprim-sulfamethoxazole.

246 a penicillin or macrolide antibiotic, or for trimethoprim-sulfamethoxazole.

247 or aadA and dhfr, which confer resistance to trimethoprim-sulfamethoxazole.

248 profloxacin, and only 7% were susceptible to trimethoprim-sulfamethoxazole.

249 mbination with ampicillin, trimethoprim, and trimethoprim-sulfamethoxazole.

250 cies are interpreted based on human data for trimethoprim-sulfamethoxazole.

251 ycycline, 29.7% to clindamycin, and 21.6% to trimethoprim-sulfamethoxazole.

252 esistant to ampicillin, chloramphenicol, and trimethoprim-sulfamethoxazole; 4 were also resistant to

253 While antifolates such as Bactrim (trimethoprim-sulfamethoxazole; TMP-SMX) continue to play

254 and levofloxacin among S. pneumoniae and for trimethoprim/sulfamethoxazole and azithromycin among H.

255 and treatment of Pneumocystis pneumonia with trimethoprim/sulfamethoxazole is effective in reducing t

256 Trimethoprim/sulfamethoxazole prophylaxis was associated

257 maining patients were randomized to Group 1 (trimethoprim/sulfamethoxazole tablet every 2 days) or Gr

258 Trimethoprim/sulfamethoxazole therapy resulted in a 100%

259 ttransplant therapy consisted of tacrolimus, trimethoprim/sulfamethoxazole, and prednisone (the latte

260 effect of aminopenicillin, fluoroquinolone, trimethoprim/sulfamethoxazole, and tetracycline usage on

261 f isolates were resistant to clindamycin and trimethoprim/sulfamethoxazole, respectively.

262 olid, minocyline, tigecycline, rifampin, and trimethoprim/sulfamethoxazole.

263 her rates of resistance to gentamicin (43%), trimethoprim-sulphamethoxazole (60%), and ciprofloxacin

264 Prophylaxis with co-trimoxazole (trimethoprim-sulphamethoxazole) is recommended for peopl

265 tics, with the exception of sulfamethoxazole-trimethoprim (SXT).

266 Several antifolates, including trimethoprim (TMP) and a series of propargyl-linked anal

267 -position were synthesized and compared with trimethoprim (TMP) and piritrexim (PTX) as inhibitors of

268 using cyclic voltammetry in the presence of Trimethoprim (TMP) as template molecules.

269 ity (DeltaG(0)(coop) = -2.9 kcal mol(-1)) of trimethoprim (TMP) binding to a bacterial dihydrofolate

270 distribution of sulfamonomethoxine (SMM) and trimethoprim (TMP) in egg yolk and white was measured du

271 of E. coli dihydrofolate reductase (DHFR) by trimethoprim (TMP) prevents growth, but this can be reli

272 ictive biophysics-based fitness landscape of trimethoprim (TMP) resistance for Escherichia coli dihyd

273 ue in spDHFR is the critical element for the trimethoprim (TMP) resistance.

274 Trimethoprim (TMP) that specifically binds to eDHFR was

275 On the basis of the high affinity binding of trimethoprim (TMP) to Escherichia coli dihydrofolate red

276 ng the enzyme-binding species selectivity of trimethoprim (TMP) with the potency of piritrexim (PTX),

277 m pjDHFR and pcDHFR with methotrexate (MTX), trimethoprim (TMP), and its potent analogue, PY957.

278 FR and its binary and ternary complexes with trimethoprim (TMP), folinic acid and coenzymes (NADPH/NA

279 gh antiparasitic vs mammalian selectivity of trimethoprim (TMP), the heretofore undescribed 2,4-diami

280 thazine, SMZ; and sulfadimethoxine, SDM) and trimethoprim (TMP).

281 ose activity is controlled by the antibiotic trimethoprim (TMP).

282 ins is regulated by the simple folate analog trimethoprim (TMP).

283 tagonists, including the antibacterial agent trimethoprim (TMP).

284 is higher than the first line clinical agent trimethoprim (TMP).

285 ction based on the small-molecule antibiotic trimethoprim (TMP).

286 sis for how baDHFR has natural resistance to trimethoprim (TMP; 2).

287 ino-5-(3',4',5'-trimethoxybenzyl)pyrimidine (trimethoprim, TMP) with the potency of 2,4-diamino-5-met

288 8 and Phe34, rationalizing weaker binding of trimethoprim to Leu100 DHFR.

289 rnary complexes with cofactor and CB3717 and trimethoprim (TOP), potent inhibitors of thymidylate syn

290 e characterized molecular mechanisms whereby trimethoprim treatment results in cell death, using Esch

291 Cloned MMTV proviruses carrying a trimethoprim (trim) cassette in the envelope gene were d

292 of mixtures of three major use antibiotics (trimethoprim, tylosin, and lincomycin) to algal and cyan

293 d low amounts of thymidine were treated with trimethoprim under aerobic and anaerobic conditions.

294 ion of thymidine and increases resistance to trimethoprim under both aerobic and anaerobic conditions

295 tetracycline, streptomycin, and sulfonamide/trimethoprim was assigned to a single mosaic region on a

296 its of detection (LOD) for sulphadiazine and trimethoprim were 0.86 and 0.92 mumolL(-1), respectively

297 -fold (C. hominis and T. gondii) relative to trimethoprim were generated by synthesizing just 14 new

298 vivo selection using the antibacterial drug, trimethoprim, where the water content of the media is de

299 an serum albumin, and the antimalarial agent trimethoprim, which interacts with dihydrofolate reducta

300 t-scale system for atenolol, metoprolol, and trimethoprim, while sulfamethoxazole and propranolol wer